Cancer-Causing Proteins Charlotte NC

The drugs, called thiazole antibiotics, appear to block a cellular protein called FoxM1, one of the most over-produced proteins in cancer cells, according to researchers at the University of Illinois at Chicago College of Medicine. FoxM1 is believed to play an important role in causing cells to become cancerous and may present a promising target for future anti-cancer treatments.

Mark Jeffrey Mogul, MD
(704) 384-1900
1712 E 4th St
Charlotte, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Suny-Hlth Sci Ctr At Syracuse, Coll Of Med, Syracuse Ny 13210
Graduation Year: 1987

Data Provided by:
John B Martinie
(704) 355-1813
1025 Morehead Medical Dr
Charlotte, NC
Specialty
Surgical Oncology

Data Provided by:
Stephen Paul McClure
(704) 384-4814
200 Hawthorne Lane
Charlotte, NC
Specialty
Hematology

Data Provided by:
Anthony Lawrence Asher, MD
(704) 376-1605
Carolina Neurosurgery and Spine Asociates 225 Baldwin Road
Charlotte, NC
Specialties
Neurological Surgery, Surgical Oncology
Gender
Male
Education
Medical School: Wayne State Univ Sch Of Med, Detroit Mi 48201
Graduation Year: 1982

Data Provided by:
Richard B Reiling, MD
(704) 384-9955
200 Hawthorne Ln
Charlotte, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
James Bryan Hall, MD
(704) 355-8650
PO Box 32861
Charlotte, NC
Specialties
Oncology (Cancer), Gynecological Oncology
Gender
Male
Education
Medical School: Med Univ Of Sc Coll Of Med, Charleston Sc 29425
Graduation Year: 1974

Data Provided by:
Mark Mogul
(704) 384-1900
1712 E 4th St
Charlotte, NC
Specialty
Hematology / Oncology, Pediatric Hematology-Oncology

Data Provided by:
Dr.James Hall
(704) 446-1545
1025 Morehead Medical Dr # 600
Charlotte, NC
Gender
M
Education
Medical School: Med Univ Of Sc Coll Of Med
Year of Graduation: 1974
Speciality
Oncologist
General Information
Hospital: Carolinas Medical Center
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 3, reviews.

Data Provided by:
Mark Kirsch, MD
(704) 384-4189
PO Box 33549
Charlotte, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of The Witwatersrand, Med Sch, Johannesburg, So Africa
Graduation Year: 1969
Hospital
Hospital: Rowan Reg Med Ctr, Salisbury, Nc; Presbyterian Hospital, Charlotte, Nc
Group Practice: Southeast Radiation Oncology Group Matthews Rad Oncology; Southeast Radiation Oncology Group Pa; Southeast Radiation Oncology Group Rock Hill Rad Oncology;

Data Provided by:
Dr.Guilherme Cantuaria
(704) 384-8200
200 Hawthorne Lane
Charlotte, NC
Gender
M
Education
Medical School: Fund Univ De Brasilia, Fac De Cien, Brasilia-Df
Year of Graduation: 1992
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
3.0, out of 5 based on 2, reviews.

Data Provided by:
Data Provided by:

Cancer-Causing Proteins

Provided By:

Scientists are closer to understanding how a recently approved class of antibiotics may work against cancer.

The drugs, called thiazole antibiotics, appear to block a cellular protein called FoxM1, one of the most over-produced proteins in cancer cells, according to researchers at the University of Illinois at Chicago College of Medicine. FoxM1 is believed to play an important role in causing cells to become cancerous and may present a promising target for future anti-cancer treatments.

The researchers also found that thiazoles may inhibit proteasomes, a molecular complex within cells that disposes of old proteins marked for destruction. Recently, a number of proteasome inhibitors have shown promise against cancer. One of these inhibitors, bortezomib (Velcade), has proven effective against a number of cancers, including myeloma and certain forms of lymphoma.

The new research, which appears in the online journal PLoS ONE, points to the possible anti-cancer use of thiazoles in the future. In a university news release, study author Andrei Gartel, an associate professor of molecular genetics, said that by using thiazole antibiotics in combination with well-known proteasome inhibitors, "we may see a synergy that allows us to markedly reduce the dose of any one of these drugs and still effectively kill the cancer cells."

More information

Read more about cancer treatments at the U.S. National Cancer Institute.

SOURCE: University of Illinois at Chicago, news release, Aug. 11, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com